CHEK
Check-Cap Ltd.
stock NASDAQ

**The Setup**
If you’ve been looking for an AI play that isn’t already trading at a 100x P/S ratio, listen up. MBAI (Check-Cap Ltd.) just finalized its transformation. This isn't the old medical tech company anymore; through a massive merger with MBody AI, it has pivoted entirely into Embodied AI, the tech that actually puts "brains" into robots.
**The Catalysts:**
Ticker Change & Merger: The company recently shifted from CHEK to MBAI. Most of the market hasn't updated its screeners yet. We are early.
Nasdaq Compliance SECURED: As of January 26, 2026, the company officially cleared its Nasdaq minimum equity hurdle. The risk of delisting is gone, clearing the way for institutional eyes.
Real Revenue/Clients: Unlike most AI "startups," MBody AI’s Orchestrator™ platform is already deployed with Fortune 500 blue-chip customers. They are automating workforces for the big players now.
**The Technology:**
The biggest problem in robotics is that different robots don’t talk to each other. MBody’s tech is hardware-agnostic. Think of it as the "Windows" or "Android" for robots. Whether it’s an autonomous cart in a hospital or a robotic arm in a factory, MBAI’s platform manages the entire fleet through one AI layer.
**The Financials / Specs:**
Market Cap: Still tiny (approx. $15M-$25M range), meaning it has massive "multi-bagger" potential if it hits the mainstream AI narrative.
Ownership: The merger received 98% shareholder approval, showing insane conviction from the base.
Price Action: We just saw a massive 80%+ spike on the compliance news. It’s cooling off/consolidating, which usually provides a "higher low" entry point for the next leg up.
**Final Verdict:**
$MBAI is one of the only ways to play "Embodied AI" on the Nasdaq without buying a $3 trillion company like Microsoft or Nvidia. If they announce one more Fortune 500 partnership, this thing could go parabolic.
Upvote4Downvote3Go to commentsShare

**The Setup**
If you’ve been looking for an AI play that isn’t already trading at a 100x P/S ratio, listen up. MBAI (Check-Cap Ltd.) just finalized its transformation. This isn't the old medical tech company anymore; through a massive merger with MBody AI, it has pivoted entirely into Embodied AI, the tech that actually puts "brains" into robots.
**The Catalysts:**
Ticker Change & Merger: The company recently shifted from CHEK to MBAI. Most of the market hasn't updated its screeners yet. We are early.
Nasdaq Compliance SECURED: As of January 26, 2026, the company officially cleared its Nasdaq minimum equity hurdle. The risk of delisting is gone, clearing the way for institutional eyes.
Real Revenue/Clients: Unlike most AI "startups," MBody AI’s Orchestrator™ platform is already deployed with Fortune 500 blue-chip customers. They are automating workforces for the big players now.
**The Technology:**
The biggest problem in robotics is that different robots don’t talk to each other. MBody’s tech is hardware-agnostic. Think of it as the "Windows" or "Android" for robots. Whether it’s an autonomous cart in a hospital or a robotic arm in a factory, MBAI’s platform manages the entire fleet through one AI layer.
**The Financials / Specs:**
Market Cap: Still tiny (approx. $15M-$25M range), meaning it has massive "multi-bagger" potential if it hits the mainstream AI narrative.
Ownership: The merger received 98% shareholder approval, showing insane conviction from the base.
Price Action: We just saw a massive 80%+ spike on the compliance news. It’s cooling off/consolidating, which usually provides a "higher low" entry point for the next leg up.
**Final Verdict:**
$MBAI is one of the only ways to play "Embodied AI" on the Nasdaq without buying a $3 trillion company like Microsoft or Nvidia. If they announce one more Fortune 500 partnership, this thing could go parabolic.
Upvote4Downvote3Go to commentsShare